Abbott Laboratories operates across four reportable segments — Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals (EPD) — a diversification that historically tempers cyclicality while exposing the company to several distinct growth curves. Medical Devices is the engine, contributing roughly 48% of sales, led by the FreeStyle Libre continuous glucose monitoring (CGM) franchise, electrophysiology, structural heart, and rhythm management. Management estimates the addressable CGM population at 75–80 million people versus roughly 15 million users today, leaving a long penetration runway even before factoring in the Libre Duo dual glucose-ketone platform. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock compares to peers in the sector.
The March 2026 Exact Sciences acquisition meaningfully strengthens the competitive moat in Diagnostics, combining Abbott's global commercial scale with market-leading noninvasive colorectal cancer screening and precision-oncology tools. On the structural side, China's volume-based procurement (VBP) policies remain a persistent pricing overhang, while significant emerging-market and international revenue exposure makes the business sensitive to foreign-exchange swings. Abbott's established-pharmaceuticals and nutrition franchises offer steady, high-single-digit and recovering contributions, respectively, but carry their own regulatory and demand risks.
The most consequential catalysts over the next several quarters are product-driven. Abbott has signaled U.S. launches of Libre Duo, the Amulet 360 left atrial appendage occluder, the TactiFlex Duo pulsed field ablation (PFA) catheter, and a coronary intravascular lithotripsy (IVL) system, while patient enrollment for trials supporting a balloon-expandable transcatheter aortic valve replacement (TAVR) valve, a leadless conduction-system pacing device, and a wearable continuous lactate monitor is set to begin in the fourth quarter. Each successful launch bolsters the credibility of management's 6.5%–7.5% comparable sales growth guidance and its "accelerating second-half" narrative.
Analyst activity has turned more cautious but remains favorable. Following a mixed Q3 2026 report in which Abbott trimmed fourth-quarter guidance and its 2027 outlook, firms including TD Cowen (price target to $118 from $135), Jefferies ($130 from $135), and RBC Capital ($125 from $130) lowered targets while retaining Buy or equivalent ratings, while Wells Fargo ($120), Baird ($123), and Citi ($125) held constructive stances. The consensus recommendation is "Strong Buy," with an average one-year price target of approximately $120, versus a recent share price near $104.
Abbott's trajectory is tied to several macro forces. Interest rates influence both the valuation of a long-duration healthcare compounder and hospital capital-spending cycles for higher-cost device systems. Persistent tariffs and input-cost inflation — most acute in Nutrition — pressure margins, while a stronger U.S. dollar dampens reported growth given substantial overseas revenue. In China, government volume-based procurement (VBP) policy continues to compress diagnostics pricing, though the largest 2025 impacts have largely lapped. Demographic tailwinds, including aging populations and rising chronic-disease prevalence, remain powerful structural supports, particularly for diagnostics, diabetes care, and established pharmaceuticals in emerging markets.
Heading into 2027, Abbott's story centers on execution of a dense device-launch calendar and integration of Exact Sciences. Consensus estimates point to full-year 2026 revenue of roughly $50 billion and adjusted earnings per share (EPS) near the $5.45–$5.60 guidance range, with further growth anticipated in 2027 as new products scale. Margin sustainability will hinge on whether premium-priced devices offset tariffs and Nutrition cost pressure, while capital-allocation priorities — including the dividend, which Abbott has raised for decades — and potential tuck-in acquisitions remain areas to watch.
Longer term, competitive threats include Dexcom in CGM, Medtronic and Boston Scientific in cardiovascular devices, and rivals in pulsed field ablation, where market-share recapture is a stated management objective. Regulatory developments, particularly U.S. Food and Drug Administration (FDA) clearances and reimbursement decisions for Libre and the Amulet 360, will shape the timing of revenue inflection. The consumer-health and artificial-intelligence initiatives, while promising optionality, are not yet embedded in guidance and should be viewed as long-dated strategic bets rather than near-term earnings drivers.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is designed to surface developing trends, evaluate potential breakouts or reversals, and support exploration of predictions across a broad range of tradable instruments. The platform incorporates searchable prediction categories, historical context, and alert-oriented functionality to help users monitor changing conditions. Investors seeking an additional, data-driven lens on names like Abbott Laboratories may find the Trend Prediction Engine a useful complement to fundamental research. In my view, it offers a practical way to cross-check near-term momentum alongside the longer-term fundamentals discussed here.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ABT declined for three days, in 169 of 298 cases, the price declined further within the following month. The odds of a continued downward trend are 57%.
The 10-day RSI Indicator for ABT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 17 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABT as a result. In 39 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
The Moving Average Convergence Divergence Histogram (MACD) for ABT turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 30 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
ABT moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
ABT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for ABT crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +5.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 170 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 126 of 258 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.722) is normal, around the industry mean (4.142). P/E Ratio (35.461) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.253). Dividend Yield (0.023) settles around the average of (0.011) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of health care products
Industry MedicalNursingServices